AN ACT relating to prescription drugs.
HB 389 is a broad prescription-drug and controlled-substances bill that updates multiple Kentucky statutes governing Medicaid medication synchronization, controlled-substance prescribing and dispensing, the prescription drug monitoring program (PDMP), and health insurance coverage for prescription-drug synchronization. It requires Medicaid and managed care organizations to offer medication synchronization for chronic conditions when agreed to by the patient, provider, and pharmacist, and it extends similar synchronization requirements to health benefit plans. The bill also removes several references to Schedule III hydrocodone products from existing controlled-substance provisions, while retaining and in some places tightening rules for Schedule II controlled substances.
The bill reinforces electronic prescribing requirements, expands and clarifies PDMP reporting and access rules, and updates the monitoring system to include medicinal cannabis-related data and users. It also requires more frequent reporting, adds training and continuing-education provisions, and authorizes additional data-sharing with certain licensing boards, law enforcement, Medicaid, and specified research or oversight entities. In addition, it maintains or strengthens restrictions on controlled-substance prescribing and dispensing, including limits tied to acute pain, recordkeeping, licensure discipline, and criminal penalties for intentional noncompliance with reporting or disclosure rules.
HB 389 would amend KRS Chapters 205, 218A, 218B, and 304 to expand medication synchronization in Medicaid and private insurance, update controlled-substance definitions and prescribing standards, and broaden the scope and operation of Kentucky’s electronic monitoring system. It affects Medicaid managed care organizations, pharmacists, prescribers, insurers, the Cabinet for Health and Family Services, licensing boards, law enforcement, and medicinal cannabis businesses and practitioners. The bill also changes reporting, confidentiality, and enforcement provisions tied to the PDMP and medicinal cannabis tracking, and it preserves or clarifies exceptions for certain settings such as hospice, nursing facilities, hospitals, research protocols, and charitable health care services.
The bill appears to have received strong House support, passing third reading 90-4, suggesting broad agreement with its prescription-drug oversight and medication-access provisions. The overall tone of the bill is regulatory and public-health oriented, with emphasis on safer prescribing, better monitoring, and easier access to chronic medications through synchronization. The absence of committee transcript debate in the provided materials limits insight into detailed floor or committee sentiment, but the vote indicates the measure was generally well received.
The main points of potential contention are the bill’s continued expansion of monitoring and reporting requirements, the criminal penalties for intentional noncompliance, and the breadth of data access granted to licensing boards, law enforcement, Medicaid, and other entities. Prescribers and pharmacists may be concerned about administrative burden, privacy, and the practical effects of tighter electronic prescribing and reporting rules. On the other hand, supporters are likely to emphasize patient convenience through medication synchronization, improved oversight of opioid and other controlled-substance prescribing, and the inclusion of medicinal cannabis in the monitoring framework.